Evidence map›Paper›PMID 32317623›Full record

ArticleSignal transduction and targeted therapy2020

NUSAP1 potentiates chemoresistance in glioblastoma through its SAP domain to stabilize ATR.

Yuzu Zhao, Jiang He, Yongsen Li, Shengqing Lv, Hongjuan Cui

Open access · goldAbstract read
In one paragraph

Article in Signal transduction and targeted therapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
51citing papers in PubMed, 1 pooled it
4.8field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

51 citing papers in PubMed, 1 synthesis or guideline pooled it, 92 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. NUSAP1 Recruits DAXX to Suppress HIF-Driven Triple-Negative Breast Cancer Progression.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Article
  5. Article
  6. Article
  7. Article
  8. The role and therapeutic value of NUSAP1 in human cancers.Journal of translational medicine · 2025
    Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. SUMO and the DNA damage response.Biochemical Society transactions · 2024
    Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Yuzu Zhao *State Key Laboratory of Silkworm Genome Biology, Southwest University, Chongqing, China.
Jiang He *State Key Laboratory of Silkworm Genome Biology, Southwest University, Chongqing, China.
Yongsen LiState Key Laboratory of Silkworm Genome Biology, Southwest University, Chongqing, China.
Shengqing LvDepartment of Neurosurgery, Xinqiao Hospital, Third Military Medical University, Chongqing, China. lvsq0518@hotmail.com.
Hongjuan CuiState Key Laboratory of Silkworm Genome Biology, Southwest University, Chongqing, China. hongjuan.cui@gmail.com.
Southwest University · CNState Key Laboratory of Silkworm Genomic BiologyXinqiao Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

NUSAP1, which is a microtubule-associated protein involved in mitosis, plays essential roles in diverse biological processes, especially in cancer biology. In this study, NUSAP1 was found to be overexpressed in GBM tissues in a grade-dependent manner compared with normal brain tissues. NUSAP1 was also highly expressed in GBM patients, dead patients, and GBM cells. In addition, NUSAP1 was found to participate in cell proliferation, apoptosis, and DNA damage in GBM cells. Ataxia telangiectasia and Rad3-related protein (ATR) are a primary sensor of DNA damage, and ATR is also a promising target in cancer therapy. Here, we found that NUSAP1 positively regulated the expression of ATR. Mechanistically, NUSAP1 suppressed the ubiquitin-dependent proteolysis of ATR. The SAP (SAF-A/B, Acinus, and PIAS) domain is a common motif of many SUMO (small ubiquitin-like modifier) E3 ligases, and this domain is involved in substrate recognition and ligase activity. This study further demonstrated that the SAP domain of NUSAP1 promoted the sumoylation of ATR, and thereby antagonized the ubiquitination of ATR. These results suggest that NUSAP1 stabilizes ATR by sumoylation. Moreover, NUSAP1 potentiated chemotherapeutic resistance to temozolomide (TMZ) and doxorubicin (DOX) through its SAP domain. Overall, this study indicates that NUSAP1 is a promising therapeutic target in GBM.

Indexed as

AnimalsApoptosisAtaxia Telangiectasia Mutated ProteinsCell ProliferationDNA DamageDoxorubicinDrug Resistance, NeoplasmFemaleGene Expression Regulation, NeoplasticGlioblastomaHeterograftsHumansMaleMiceMicrotubule-Associated ProteinsSumoylationAtaxia Telangiectasia Mutated ProteinsATR protein, humanDoxorubicinMicrotubule-Associated ProteinsNUSAP1 protein, humanTemozolomideUbiquitin-Protein Ligases

Identifiers

PMID32317623
PMCPMC7174393
OpenAlexW3016723855

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.